News list

2010-03-11 | Life sciences

BT Pharma secures EUR 13.1M (USD 17.7M) in capital funding

BT Pharma, a biopharmaceutical company developing innovative immunotherapies announces today that it has raised 13.1 million Euro in additional funding and changed its name to Genticel.

Find out more

2010-02-23 | Life sciences

GlycoVaxyn’s First Clinical Study with Bioconjugate Vaccine

Study to Evaluate Safety, Reactogenicity and Immunogenicity of Vaccine Against Shigella dysenteriae

Find out more

2010-01-14 | Life sciences

BIOTRONIK and Endosense Sign International Exclusive Distribution Partnership

BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies and Endosense, a Swiss medical technology company today announced that they have entered into an exclusive distribution agreement for Endosense’s force-sensing ablation catheter, the TactiCath®. Under the terms of the agreement, BIOTRONIK will be the exclusive distributor of the TactiCath in all major markets outside of the United States, Japan and Asia.

Find out more

2010-01-08 | Life sciences

EdRIP invests in Covagen

Covagen extends financing round and adds Edmond de Rothschild Investment Partners (EdRIP) to investor syndicate.

Find out more

2009-12-23 | Life sciences

Novexel to be acquired by AstraZeneca

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing.

Find out more

2009-12-17 | Life sciences

REGADO BIOSCIENCES, INC. completes $40 Million Series D financing

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing. The round, led by new investor Edmond de Rothschild Investment Partners, part of The Edmond de Rothschild Rothschild Group, was joined by existing investors Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors.

Find out more

2009-12-10 | Life sciences

Endosense Board Appointments

Endosense names Jan H. Egberts, M.D. Chairman of the Board, adds Michael J. Dormer as new Board Director

Find out more

2009-12-03 | Life sciences

NOXXON Pharma AG achieves milestone in partnership with Eli Lilly and Company

NOXXON Pharma, the biopharmaceutical company focusing on the development of novel medicines based on its unique proprietary Spiegelmer® technology, announced today the achievement of an important milestone in its drug discovery and development partnership with Eli Lilly and Company.

Find out more

2009-11-12 | Life sciences

PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott (NYSE: ABT) under which Abbott will acquire the global rights to this novel biologic.

Find out more

2009-11-02 | Life sciences

NOXXON announces first-in-human clinical trial with Spiegelmer® NOX-A12

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12.

Find out more

2009-10-30 | Life sciences

EdRIP invests in PDC Biotech

PDC Biotech GmbH (PDC) today announced the close of a Series A financing of over €4 million. Edmond de Rothschild Investment Partners co-led the round.

Find out more

2009-10-12 | Life sciences

NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer® NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its antiinflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

Find out more

2009-09-03 | Life sciences

NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12

NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (“KMU-Innovativ”). The grant was presented to NOXXON following the completion of a peer reviewed selection process.

Find out more

2009-09-01 | Life sciences

EdRIP invests in Endosense SA

Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.

Find out more

2009-06-08 | Life sciences

NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer®

NOXXON Pharma AG (NOXXON) announced today the successful initial dosing of healthy volunteers with Spiegelmer® NOX-E36 in the company’s first-in-human clinical trial.

Find out more

2009-06-08 | Life sciences

PanGenetics receives approval for clinical evaluation of anti-NGF antibody in patients with chronic pain

PanGenetics B.V. announced today that the Competent Authority of the Netherlands has approved the Clinical Trials Application for a first-in-man study with antibody PG110.

Find out more

2009-04-06 | Life sciences

JenaValve names Michael J. Dormer as Chairman of the Board

JenaValve™ Technology,Inc., a medical device company specialized in developing minimally-invasive heart valve replacement systems, today announced the appointment of Mr. Michael J. Dormer as Chairman of the Board of Directors, effective March 1st, 2009.

Find out more

2009-03-05 | Life sciences

GlycoVaxyn AG Raises CHF 25 Million in Financing Led

GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, today announced the successful closing of a CHF25 million (ca. US$22 million, €17 million) Series B financing. The round was led by Edmond de Rothschild Investment Partners.

Find out more

2008-11-07 | Life sciences

Phase II for Novexel's NXL 104

Novexel announces that its most advanced injectable antibacterial, NXL104,with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical.

Find out more

2008-10-23 | Life sciences

Novexel : Positive Phase II Trial Results with NXL103

Novexel announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP).

Find out more

2008-10-23 | Life sciences

New CSO for Novexel

Novexel appoints Kenneth Coleman as its new Chief Scientist Officer (CSO).

Find out more

2008-10-23 | Life sciences

€20 million capital funding for SuperSonic Imagine

SuperSonic Imagine announces a second fund-raising round of €20 million, led by Edmond de Rothschild Investment Partners.

Find out more

2008-10-06 | Life sciences

Clinical evaluation approval for PanGenetics

PanGenetics B.V. announced today that the company has received formal regulatory approval to initiate clinical evaluation of the company’s CD40 antagonist antibody, PG102. The multi-centre trial in Hungary and Serbia will recruit patients with active psoriatic arthritis, and is designed as a double blind, placebo controlled, single ascending dose study.

Find out more

2008-09-26 | Life sciences

Novagali Pharma completes a €15 million fund raising

Novagali Pharma, a French Laboratory specialized in ophthalmology announces today it has secured €15 million in a new financing round with the participation of the historical Company investors.

Find out more

2008-09-17 | Life sciences

New round for BT Pharma

BT PHARMA, a biopharmaceutical firm developing novel immunotherapeutics for HPV associated diseases and cancers, is pleased to announce that it has successfully closed a new financing round of € 2 825 000. The round was led by Edmond de Rothschild Investment Partners.

Find out more

2008-05-27 | Life sciences

EdRIP closes € 150 million, Biodiscovery 3 Fund

Edmond de Rothschild Investment Partners today announced it has raised €150 million through its BioDiscovery 3 venture capital fund for European life science companies. The closing of BioDiscovery 3 brings the total funds under management for life science investments close to €300 million. Along with this first and final closing, Edmond de Rothschild Investment Partners has opened a greenshoe of up to 10% for additional investors.

Find out more

2008-01-22 | Life sciences

NOVEXEL et FOREST LABORATORIES announce licence agreemen

NOVEXEL et FOREST LABORATORIES announce licence agreement for NXL104, a bnovel broad-spectrum beta lactamase inhibitor.

Find out more

» Toutes les actualités

Affichage des annonces ‭[2]‬

2010-03-08 | Development capital

Stéphane Dondain, CEO of Group Iranex, has raised his stakes to become the main shareholder in the company with Edmond de Rothschild Investment Partners

Stéphane Dondain, CEO of Groupe Iranex and operations director for more than 10 years, has raised his stake to close to 76% to become the main shareholder in the company. Edmond de Rothschild Investment Partners has bought around 24% via the Winch Capital 2 FCPR fund.

Find out more

2010-02-16 | Development Capital

Winch Capital 2, run by Edmond de Rothschild Investment Partners, has made it first investment

The senior management of Groupe SEGEX, along with UI Gestion and Socadif, have chosen Edmond de Rothschild Investment Partners to lead an OBO transaction and embark on a new development cycle.

Find out more

2010-02-16 | Development Capital

Edmond de Rothschild Investment Partners has won an award in Private Equity Magazine’s “Grand Prix”

Edmond de Rothschild Investment Partners was awarded first prize in the Development Capital category in Private Equity Magazine’s “Grand Prix”.

Find out more

2009-11-19 | Press release

EUR 250M target reached for final closing of the Winch Capital2 Private Equity Fund

After a first closing on June 30 2009 for EUR 175m, Edmond de Rothschild Investment Partners is pleased to announce the final closing of its Winch Capital 2 development capital fund for EUR 250m.

Find out more

2009-07-08 | Private equity

Edmond de Rothschild Investment Partners completes the first closing of Winch Capital 2 for €175 million, exceeding the announced objective

On June 30, 2009, Edmond de Rothschild Investment Partners completed the first closing of its Winch Capital 2 growth-capital fund for €175 million. This initial amount already exceeds the size of Winch Capital 1 (€165 million), raised in December 2005 by the same team.

Find out more

» Toutes les actualités

2010-02-17 | Interview

Ariane de Rothschild: Interview in Swiss Style Magazine

The Baroness Benjamin de Rothschild embodies the family's commitments

Find out more

2010-01-14 | Information

La Compagnie Financière Edmond de Rothschild : Review of our activity in 2009

In 2009, La Compagnie Financière Edmond de Rothschild’s private banking and asset management divisions pursued their growth in France and internationally.

Find out more

2010-01-14 | information

Investment strategy 2010

Get access to our 2010 Investment Strategy and our fund managers' analysis and recommendations for each asset class.

Find out more

2009-11-09 | Press release

Group Edmond de Rothschild: appointments within the holding company and the Bank in France

The Supervisory Boards of CFSH and La Compagnie Financière Edmond de Rothschild Banque, which are chaired by Benjamin de Rothschild, the Group’s family shareholder, have made two nominations.

Find out more

2009-10-29 | Press release

Reinforced cooperation between La Compagnie Financière Edmond de Rothschild and Bank of China

After successfully launching joint financial products for Bank of China’s network in 2009, both groups are committed to intensifying their cooperation from 2010 in asset management and the selection of investment funds as well as in designing and marketing private banking products and services.

Find out more

2009-09-28 | Private banking

La Compagnie Financière Edmond de Rothschild's private banking business has been ranked 1st in the latest Private Banking strategy Survey 2009 carried out by amGroup

The study shows that La Compagnie Financière Edmond de Rothschild has once again retained its position as N°1 in French private management. C onsidered as a pure player by others in its peer group, the Bank is cited as a model firm because of its history, its image and the efficient links between its various businesses.

Find out more

» Toutes les actualités

News list

Affichage des annonces ‭[2]‬

Warning

Investor Login